Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series

Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria

(2014) Bilal Hameed et al.   LIVER TRANSPLANTATION

Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence

(2013) Christian Toso et al.   JOURNAL OF HEPATOLOGY

Single HCC in Cirrhotic Patients: Liver Resection or Liver Transplantation? Long-term Outcome According to an Intention-to-treat Basis

(2012) Gonzalo Sapisochin et al.   ANNALS OF SURGICAL ONCOLOGY

A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability

(2012) Manuel Rodríguez-Perálvarez et al.   ANNALS OF SURGICAL ONCOLOGY

Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria

(2012) Christophe Duvoux et al.   GASTROENTEROLOGY

Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge

(2012) Martin-Walter Welker et al.   TRANSPLANT INTERNATIONAL

Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion

(2010) Derek DuBay et al.   ANNALS OF SURGERY

Management of Hepatocellular Carcinoma Recurrence After Liver Transplantation

(2010) A. Valdivieso et al.   TRANSPLANTATION PROCEEDINGS

Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation

(2010) Derek A. DuBay et al.   HPB

Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: Clinical patterns and outcome variables

(2009) A. Kornberg et al.   EJSO

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

(2008) Vincenzo Mazzaferro et al.   LANCET ONCOLOGY